# First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

> **NCT04974944** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 172 (estimated)

## Conditions studied

- Stage IVB Cervical Cancer
- Recurrent Cervical Cancer
- Persistent Cervical Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04974944
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-30
- **Primary completion:** 2023-12
- **Final completion:** 2024-12
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2021-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04974944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04974944, "First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04974944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*